{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.22","value":"-0.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"CFB at Follow-up Month 2"},{"categories":[{"measurements":[{"comment":"Standard deviation was not evaluable due to low number of participants.","groupId":"OG000","spread":"NA","value":"0.15"},{"groupId":"OG001","spread":"0.22","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"title":"CFB at Follow-up Month 4"},{"categories":[{"measurements":[{"comment":"Standard deviation was not evaluable due to low number of participants.","groupId":"OG000","spread":"NA","value":"0.15"},{"groupId":"OG001","spread":"0.19","value":"0.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"title":"CFB at Follow-up Month 6"},{"categories":[{"measurements":[{"comment":"Standard deviation is non-evaluable due to low number of participants.","groupId":"OG000","spread":"NA","value":"0.15"},{"groupId":"OG001","spread":"0.21","value":"0.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"101"}],"units":"Participants"}],"title":"CFB at Follow-up Month 8"},{"categories":[{"measurements":[{"comment":"Standard deviation was not evaluable due to low number of participants.","groupId":"OG000","spread":"NA","value":"0.15"},{"groupId":"OG001","spread":"0.20","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"CFB at Follow-up Month 10"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.18","value":"0.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"CFB at Follow-up Month 12"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.19","value":"0.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"CFB at Follow-up Month 14"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.19","value":"0.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"title":"CFB at Follow-up Month 16"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.18","value":"0.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"title":"CFB at Follow-up Month 18"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.20","value":"0.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"CFB at Follow-up Month 20"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.24","value":"0.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"CFB at Follow-up Month 22"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.22","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"title":"CFB at Follow-up Month 24"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.25","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"title":"CFB at Final Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"158"}],"units":"Participants"}],"description":"EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (\"confined to bed\"). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"MEAN","populationDescription":"ITT population (Obinutuzumab + Bendamustine arm only). Here, number of participants analyzed signified those participants who were evaluable for this outcome and \"n\" signified those participants who were evaluable for a specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final follow-up (up to 2 years after end of induction) (End of induction = up to Month 6)","title":"CFB in EuroQol 5D (EQ-5D) - Health State Profile Utility Score During Maintenance Phase","type":"SECONDARY","unitOfMeasure":"units on a scale"}